Copyright © 2002 by the European Society of Cardiology.
Editorials
The Gly389Arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies?
UCL Centre for Cardiovascular Genetics, Rayne Institute, London, U.K.
References
- White HL. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eur Heart J. 2002;23:10871092
[Abstract/Free Full Text] - Brull DJ, Montgomery HE, Sanders J. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21:14581463
[Abstract/Free Full Text] - Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274:1267012674
[Abstract/Free Full Text] - Xie HG, Dishy V, Sofowora G. Arg389Gly beta1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics. 2001;11:191197[CrossRef][ISI][Medline]
- Buscher R, Belger H, Eilmes KJ. In-vivo studies do not support a major functional role for the Gly389Arg beta1-adrenoceptor polymorphism in humans. Pharmacogenetics. 2001;11:199205[CrossRef][ISI][Medline]
- O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta 1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Colch). 2000;99:233238[Medline]
- Bengtsson K, Melander O, Orho-Melander M. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation. 2001;104:187190
[Abstract/Free Full Text] - Ohtsuka T, Hamada M, Hiasa G. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412417
[Abstract/Free Full Text] - Brull DJ, Sanders J, Rumley A. Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol. 2001;88:431433[CrossRef][ISI][Medline]
- Liuzzo G, Rizzello V. C-reactive protein and primary prevention of ischemic heart disease. Clin Chim Acta. 2001;311:4548[CrossRef][ISI][Medline]
- Bristow MR, Ginsburg R, Umans V. B1 and B2 adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective B1 receptor down-regulation in heart failure. Circ Res. 1986;59:297309
[Abstract/Free Full Text] - Hall JA, Petch MC, Brown MJ. In vivo demonstration of cardiac beta 2 adrenoreceptor sensitization by beta1 antagonist treatment. Circ Res. 1991;69:959964
[Abstract/Free Full Text] - von Kanel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on haemostasis in vivo. Eur J Haematol. 2000;65:357369[CrossRef][ISI][Medline]
This article has been cited by other articles:
![]() |
S. L. Kirstein and P. A. Insel Autonomic Nervous System Pharmacogenomics: A Progress Report Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Schunkert and J Erdmann Well kept secrets of the genome Eur. Heart J., March 2, 2003; 24(6): 501 - 503. [Full Text] [PDF] |
||||
![]() |
L. Swan, D.H. Birnie, S. Padmanabhan, G. Inglis, J.M.C. Connell, and W.S. Hillis The genetic determination of left ventricular mass in healthy adults Eur. Heart J., March 2, 2003; 24(6): 577 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Meisel, K. Kopke, I. Roots, M. L. Maitland, M. Gomberg-Maitland, J. Little, M. Gwinn, M. Khoury, S. L.R. Kardia, A. M. Levin, et al. Polymorphisms of Adrenergic Receptors and the Risk of Heart Failure N. Engl. J. Med., January 30, 2003; 348(5): 468 - 470. [Full Text] [PDF] |
||||
![]() |
R. J.G. Peters and S. M. Boekholdt Gene Polymorphisms and the Risk of Myocardial Infarction -- An Emerging Relation N. Engl. J. Med., December 12, 2002; 347(24): 1963 - 1965. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


